Marshall Wace
KLRA icon

Marshall Wace’s Kailera Therapeutics KLRA Stock Holding History

Marshall Wace’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10M Buy
+878,196
New +$14.8M 0.01% 978

Other funds holding KLRA

Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Royalty Pharma Sub-Manager
Royalty Pharma Sub-Manager New York $196M AUM 16.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Marshall Wace's KLRA Position: Q3 2026 in Review

Marshall Wace opened a new position in Kailera Therapeutics (KLRA) in Q3 2026: 878,196 shares worth $10M. The stake represents 0.01% of the portfolio and ranks #978 among its holdings.

82 funds tracked by Wall St. Rank hold KLRA as of Q3 2026.

  • Marshall Wace held 878,196 shares of Kailera Therapeutics worth $10M as of Q3 2026.
  • Kailera Therapeutics was a new Marshall Wace position in Q3 2026.
  • Kailera Therapeutics made up 0.01% of Marshall Wace's portfolio in Q3 2026, its #978 holding.
  • 82 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.